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ABSTRACT Herpes simplex virus (HSV) encodes a DNA
polymerase that is similar in several respects to the replicative
mammalian DNA polymerase a. Recently, these and other
DNA polymerases have been shown to share several regions of
protein sequence similarity. Despite these similarities, antiviral
drugs that mimic natural polymerase substrates specifically
inhibit herpesvirus DNA polymerases. To study amino acids
involved in substrate and drug recognition, we have charac-
terized and mapped altered drug sensitivity markers of nine
HSV pol mutants and sequenced the relevant portions of these
mutants. The mutations were found to occur within four
relatively small regions. One such region, which we designate
region A, has sequence similarity only to DNA polymerases that
are sensitive to certain antiviral drugs. The other three regions
contain sequences that are similar among various DNA poly-
merases. The multiple mutations occurring within two of these
regions make it likely that the regions interact directly with
drugs and substrates. Our results lead us to favor a model in
which protein folding allows interactions among the four
regions to form the substrate and drug binding sites.
DNA polymerases are central enzymes in DNA replication.
In prokaryotic systems, studies of DNA polymerases have
been greatly aided by model systems to which both genetic
and biochemical methods can be applied. The herpes simplex
virus (HSV) DNA polymerase, which is essential for HSV
replication (1), provides such a model system for the study of
eukaryotic DNA polymerases. This enzyme resembles the
mammalian replicative DNA polymerase a (pol a) in several
respects, including nuclear localization (2) and sensitivities to
inhibitors such as aphidicolin (3-7) and dideoxythymidine
triphosphate (4). Recently, HSV DNA polymerase (HSV
pol), DNA polymerase I of yeast, a variety of animal and
bacterial virus DNA polymerases, and pol a were shown to
share six regions of striking sequence similarity (8-19). Of the
viral polymerases sequenced to date, however, HSV pol
appears most closely related to pol a (8). The six regions of
sequence similarity have been designated regions I-VI by
Wong et al. (8), with region I being most similar among the
various polymerases and region VI being the least similar
(Fig. 1). Such sequence similarities suggest conservation
during evolution and important functional roles for these
regions.
Despite these similarities, HSV pol is more sensitive than
pol a to a number of inhibitors and thus serves as the ultimate
target for a number of selective antiviral drugs. These include
the pyrophosphate (PP,) analogs phosphonoacetic acid (PAA)
and phosphonoformic acid (20, 21), and the triphosphates of
nucleoside analogs such as acyclovir (ACV), vidarabine,
ganciclovir, and bromovinyldeoxyuridine (BVdU) (22-25). In
addition, aphidicolin appears to inhibit HSV pol competitively
with certain deoxynucleoside triphosphates (dNTPs) (5-7).
The availability of viral pol mutants that exhibit altered
sensitivities to these drugs permits a unique combined phar-
macological and genetic approach for investigating polymer-
ase substrate recognition. Since the various drugs mimic
and/or compete with the natural dNTP and PP1 substrates for
enzyme binding (5-7, 22-26), mutations that alter polymerase
sensitivity to these agents can be expected to identify amino
acids involved in recognition of dNTPs and PP1. We wished
to determine whether any such amino acids were located in
regions of sequence similarity with pol a and other viral DNA
polymerases, indicating functional roles for these regions. On
the other hand, identification and subsequent characteriza-
tion of regions of HSV pol that differ from pol a, yet are
involved in drug recognition, could aid in the design of more
selective, targeted antiviral agents.
Since any given mutation might affect drug and substrate
recognition indirectly, it is important to study enough muta-
tions so that clusters might be revealed, suggesting direct
participation ofregions ofamino acids in recognition. Toward
this end, we have characterized the drug sensitivity pheno-
types of a variety ofHSV pol mutants derived from wild-type
HSV type 1 strain KOS (23, 26-32), and we have mapped
such altered drug sensitivity phenotypes from each mutant to
a region of the pol gene of 1010 base pairs or less (ref. 9;
H.C.C., J.S.G., and D.M.C., unpublished data). This has
permitted us to use DNA sequencing to identify nine different
amino acids involved in drug recognition, and presumably
substrate recognition, and to compare their locations with the
regions of sequence similarity between HSV pol and human
pol a.
MATERIALS AND METHODS
Cloning and Sequencing of Mutants. Relevant properties of
the mutants used and map locations of selected markers
(H.C.C., J.S.G., and D.M.C., unpublished data) are shown
in Table 1. For mutants tsD9 and PFAT2, viral DNA, prepared
as described (9), was digested with EcoRI, and the EcoRI M
fragment (map units 0.422-0.448) was isolated as described
(9). The EcoRI M fragment was then further cut with Xho I
and Kpn I and ligated into M13mpl8 and M13mp19 digested
with Sal I and Kpn I. The EcoRI M fragment ofmutant PAAr5
was digested with Kpn I and BamHI and ligated into similarly
digested M13mpl8 and M13mpl9. For each of the other
mutants, the isolated EcoRI M fragment was ligated into
EcoRI-digested bacteriophage M13mp19 DNA. Phage con-
taining inserts in each orientation were derived for each
mutant, and relevant portions ofthe resulting single-stranded
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FIG. 1. Regions of sequence similarity of HSV pol with other DNA polymerases. Top line, HSV pol predicted protein product. Solid boxes,
regions I-VI of sequence similarity described by Wong et al. (8), and region A described in this paper. Boxed areas below indicate protein
sequence similarities shared among HSV and the indicated DNA polymerases. Areas corresponding to regions I-VI are indicated by degrees
of shading roughly corresponding to the degree of sequence similarity found among the various polymerases, with region I having the most and
region VI having the least amount of shading. The DNA polymerases listed are arranged according to their degree of sequence similarity with
HSV. EBV, Epstein-Barr virus; VV, vaccinia virus; Hum, human DNA polymerase a; AdV, adenovirus; T4, bacteriophage T4; q629,
bacteriophage )29.
DNAs were sequenced with an M13 universal primer, and,
when necessary, oligonucleotide primers were designed by
using the wild-type HSV strain KOS sequence. The following
synthetic oligonucleotides were used: GGAGACCGCCGG-
CCGGCACGT (amino acid positions 688-694), GGTT-
CACGTGAAACCCGG (positions 712-706), TCAAGGTCG-
TGTGTAAC (positions 810-815), GTTACACACGACCTTh
GA (positions 815-810), CGCGCTGTTTCTGCCCC
(positions 915-921), and TCAGCAGCAGCTTGGTG (posi-
tions 936-930). Sequencing was performed by the chain
termination method (34) essentially as described (9), with
Sequenase (United States Biochemical, Cleveland) (35) used
in some reactions according to the manufacturer's recom-
mendations.
RESULTS
Overview of Mutation Locations and Properties. Table 1
summarizes phenotypic and mapping data for nine HSV pol
mutants. Because these mutants were derived by five differ-
ent regimens and because they exhibit distinct phenotypic
properties, we expected to identify different mutations in
each mutant. Altered drug sensitivity markers in each mutant
were mapped to specific regions of the pol gene by marker
rescue techniques. These studies allowed localization of the
mutational changes responsible for altered drug sensitivities
to regions encoding 229 amino acids or less and will be
reported separately (H.C.C., J.S.G., and D.M.C., unpub-
lished data). Altered drug sensitivity markers that have been
demonstrated by marker rescue to map exclusively to par-
ticular regions of the pol gene are listed in Table 1. We report
here the sequence changes responsible for altered drug
sensitivities. Rather than sequence the entire pol gene from
each mutant, only the portion of each mutant pol gene to
which altered drug sensitivity markers mapped was se-
quenced, as listed in Table 1. Each mutant had a unique
amino acid change that is responsible for particular alter-
ations in drug sensitivity. As shown in Fig. 2, these mutations
are located in four relatively small regions within the HSVpol
gene, three of which correspond to regions of sequence
similarity shared with cellular and viral DNA polymerases.
By analysis of recombinant viruses derived by marker
rescue, three of the mutants, ACGr4, tsD9, and AraAr9, must
carry additional mutations that map outside the regions
sequenced but contribute to the phenotypes associated with
these mutants (H.C.C., J.S.G., and D.M.C., unpublished
data). The phenotypes that we have assigned to individual
mutations in these mutants may be modified by the presence
of the additional still unmapped mutations. It should be
possible to use recombinants derived in mapping experiments
to locate the additional mutations.
Mutations in a Region Containing Little or No Sequence
Similarity with pol a. The first group of mutations, shown in
Fig. 2A, includes those in tsD9 and PFAr2. These mutations
Table 1. Phenotypes of and mutations in the mutants studied
Markers mapped Map Region Nucleotide Amino acid
Mutant ACV PAA Aph Other location sequenced change change
tsD9 r r/s ts 536-696 536-696 G-2122 to A Glu-597 to Lys
PFAr2 r r hs 588-696* 536-925 A-2029 to G, Thr-566 to Ala,
C-2147 to T Ala-605 to Val
PFAr1 r r hs/s 696-925 696-925 A-2431 to Gt Arg-700 to Gly
PFAr5 r r hs 696-925 696-925 G-2504 to A Ser-724 to Asn
PAArC r r hs 696-925 696-925 C-2722 to A Pro-797 to Thr
AraAr13 r r hs BVdU 696-925 696-925 G-2770 to A Val-813 to Met
ACGr4 hs/s 696-925 696-925 C-2795 to T Thr-821 to Met
PAAr5 r r hs 696-925 696-925 C-2857 to A Arg-842 to Ser
AraAr9 r r/s hs/s DHpGhsAraAr 925-1008 925-1008 C-3216 to A Asn-961 to Lys
Coordinates of marker locations and regions sequenced are listed in terms of the amino acid sequence of the pol major open reading frame.
Map locations were determined in ref. 9 and by H.C.C., J.S.G., and D.M.C. (unpublished data). Only a subset of the altered drug sensitivity
phenotypes are listed. The nucleotide changes listed are based on the distance from the center of the palindrome at the origin of replication,
oriL. The major pol transcript initiates at approximately nucleotide 126 (33). ACV, acyclovir; Aph, aphidicolin; ts, temperature-sensitive; r,
resistant; s, sensitive; hs, hypersensitive; DHPG, ganciclovir; araA, vidarabine.
*The original map coordinates for the Aphhs marker of PFAT2 (9) were incorrect.
tAn error in ref. 9 at nucleotide 2432 (A instead of the correct G) resulted in a lysine being mistakenly reported at amino acid 700 instead of




















































REGIONS III AND VI
VI III
HSV 772 SLLSILLRDWLAMRKQIRSRIPQ--SSPEEAVLLDKQQAAIKVVCNSVYGFTGVQHGLLPCLHVAATVTTIGRtEML
:::::::: :::: .:::: :::;:::: :: ::.






























FIG. 2. Locations of HSV pol mutations that affect drug sensitivity. Alignment of select polymerases sharing sequence similarity is
presented. Amino acids identical to that found in HSV are indicated with a colon. Gaps of amino acids that aid in alignment are indicated by
hyphens. Shown are the groups of mutations that lie in or near region A (A), region 11 (B), regions III and VI (C), and region V (D). The limits
of the regions are indicated by the dashed line. Relevant phenotypes conferred by the designated mutations are listed under the names of the
mutants. Amino acids are designated by the single-letter code. Abbreviations are the same as in Table 1.
alter amino acids within a region of the HSV pol gene that
shares little or no sequence similarity with human pol a (8).
We designate this region A. Region A does contain sequences
similar to those found in pol genes of other herpesviruses
(e.g., Epstein-Barr virus; Fig. 2A) and, to a lesser extent
(20% identity; Fig. 2A), vaccinia virus (10-12, 14, 17, 18). The
limits of region A are defined by the sites at which the HSV
and vaccinia virus sequences diverge. The mutation in tsD9,
which confers resistance to ACV, marginal resistance to
PAA, and temperature sensitivity, entails a nonconservative
change from an acidic amino acid (glutamic acid) to a basic
amino acid (lysine) at position 597. Interestingly, a lysine is
found in the corresponding position in the vaccinia virus
DNA polymerase. Mutant PFAr2 contains two mutations in
this vicinity, a threonine to alanine substitution at position
566 and a more conservative alanine to valine substitution at
position 605. We predicted that the latter mutation would
prove more important to the drug-resistance phenotype
because an alanine is found at position 566 in several
wild-type strains of HSV-1 (36-38). This prediction was
verified by marker rescue analysis with DNA fragments
generated by a restriction enzyme that cuts the pol gene
between these two positions (H.C.C., J.S.G., and D.M.C.,
unpublished data). Thus, the conservative alanine to valine
change at position 605 accounts for this mutant's resistance
to PAA, ACV, and hypersensitivity to aphidicolin. The
amino acids altered in tsD9 and PFAr2 in region A occur at
residues that are conserved in all the other herpesvirus DNA
polymerases that have been sequenced to date (10-12, 18).
Mutations in Region II. Two of the mutations lie within
region II, one of six regions that share sequence similarity
with human pol a, yeast DNA polymerase I, and various viral
DNA polymerases (8) (Fig. 2B). The mutation in PFArl that
confers resistance to PAA, ACV, and marginal hypersensi-
tivity to aphidicolin is a relatively nonconservative arginine
to glycine change at position 700. This position is highly
variable among the cellular and viral polymerases. In con-
trast, the mutation in mutant PFA'5 that confers resistance to
PAA, ACV, and hypersensitivity to aphidicolin is a conserv-
ative serine to asparagine change at position 724. The serine
at this position is found in all the herpesvirus DNA poly-
merases and almost every other polymerase that shares this
region of sequence similarity (8-19, 39). Asparagine is found
at this position in the vaccinia virus DNA polymerase.
Mutations in Sequences Including Region m. Four of the
mutations lie in a segment that includes the region of
sequence similarity that has been designated region III by
Wong et al. (8) (Fig. 2C). Three of these lie within region III
itself. The mutation in AraArl3 that confers resistance to
PAA, ACV, and the ACV congener buciclovir (28), and
hypersensitivity to aphidicolin and the nucleoside analog
13VdU, is a conservative valine to methionine change at
position 813. Methionine is found at this position in the qb29
DNA polymerase (15). This position is highly variable among
the cellular and viral polymerases; however, it is two amino
acids away from an invariant lysine at position 811 and an
invariant asparagine at position 815. The mutation in ACGF4
that confers marginal hypersensitivity to aphidicolin is a
relatively nonconservative threonine to methionine change at
position 821. A threonine at this position is found in all other
herpesvirus DNA polymerases (10-12, 18, 39). Methionine is
found at this position in vaccinia virus DNA polymerase. The
mutation in PAA'5 that confers resistance to PAA and ACV
and hypersensitivity to aphidicolin is a relatively noncon-
servative arginine to serine change at position 842. Arginine
has been found at this position in all of the herpesvirus DNA
polymerases (10-12, 18, 39) and in several of the other viral
and cellular polymerases examined thus far.
The fourth mutation in this region, which lies just outside
the stated boundaries of region III, is found in mutant PArC
and is a relatively nonconservative proline to threonine
change at position 797. This mutation confers resistance to
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PAA and ACV and hypersensitivity to aphidicolin. Position
797 in HSV pot lies only seven amino acids upstream from the
stated N-terminal boundary of region III and seven amino
acids downstream from the stated C-terminal boundary ofthe
sequence designated as region VI (8). A proline is found in a
similar position in human pol a, yeast DNA polymerase I,
and in several herpesvirus DNA polymerases (8, 10, 12, 18,
39). A threonine is found in a similar position in vaccinia virus
DNA polymerase (14).
A Mutation in Region V. The mutation in AraAr9 that
confers hypersensitivity to ganciclovir, and resistance to
ACV and vidarabine lies within the sequence designated as
region V by Wong et al. (8) (Fig. 2D). This mutation is a
relatively nonconservative asparagine to lysine change at
position 961. The amino acids at this position vary among
asparagine, aspartic acid, and threonine in the cellular and
viral polymerases that share this sequence; however, the
amino acids two positions upstream and downstream are the
same in most of the viral and cellular polymerases that share
region V.
DISCUSSION
A Variety of Amino Acid Substitutions Can Confer Altered
Drug Sensitivity. We have identified nine different amino acid
substitutions that confer altered drug sensitivity. We found
no preference for conservative mutations or mutations at
amino acids that are shared among most DNA polymerases
or among herpesvirus DNA polymerases. In contrast, Larder
et al. (37) found that five of six pol lesions in ACV-resistant
mutants were conservative substitutions in amino acids
shared by other herpesvirus DNA polymerases.
Generally; HSV mutants that are resistant to PP, analogs
are hypersensitive to aphidicolin (29, 32). Of six such muta-
tions in this study, two (PAAr5 and PFAr1) correspond to the
suggestion (3) that this could be due to substitutions of basic
amino acids to more neutral amino acids, which might lessen
the affinity for acidic compounds such as PAA and increase
the affinity for hydrophobic aphidicolin. Perhaps the other
four changes alter the protein such that nearby basic amino
acids are less accessible to the drugs. Alternatively, recog-
nition of PP1 analogs and aphidicolin may depend on more
than the basic or neutral nature of amino acid side chains.
Substitutions to Amino Acids Found in Other DNA Poly-
merases. Four of the mutations that confer aphidicolin hyper-
sensitivity change amino acids to those found at the analo-
gous position in vaccinia virus DNA polymerase or 429 DNA
polymerase. Despite this, both vaccinia virus and 429 DNA
polymerases are substantially less sensitive to aphidicolin
than is wild-type HSV DNA polymerase (5, 40). This indi-
cates that other amino acid sequence differences among these
viral polymerases account for their relative aphidicolin sen-
sitivities; such other differences may be viewed as naturally
occurring second-site suppressor mutations.
Grouping of Mutations Conferring Altered Drug Sensitivity.
The rather large number of amino acid substitutions that can
cause alterations in drug sensitivity fall within four relatively
small regions in the HSV pol gene. The grouping is strength-
ened by the inclusion of five other pol mutations from
drug-resistant mutants identified by other groups (37, 38, 41).
Since the drugs to which the mutants exhibit altered sensi-
tivity mimic and/or compete with natural dNTP and PP,
substrates, these regions-A, II, III, and V-appear to be
involved, directly or indirectly, in binding both the drugs and
the corresponding substrates. The altered drug sensitivity
mutations fall between amino acids 597 and 961, appearing to
confirm our original proposal (9) that this portion of the HSV
pol polypeptide folds to form part of a domain containing
substrate and drug binding sites.
There has been one report of a drug-resistant pol mutant
containing a mutation outside this portion of the pol gene.
This mutant, TP2.5, contains the same serine to asparagine
mutation at position 724 that we have identified in mutant
PFAT5 along with a glycine to aspartic acid change at position
335 (37) and exhibits altered drug sensitivity phenotypes
similar to those ofPFA'5 (42). Thus, the mutation at position
724 seems sufficient to account for the phenotypes of TP2.5
(this report; H.C.C., J.S.G., and D.M.C., unpublished data).
Regions II and m Are Likely to Participate Directly in
Substrate Recognition. Of the nine altered drug sensitivity
mutations identified in this study, two lie within region II and
three lie within region III (Fig. 2 B and C). Four other HSV
pol mutations in drug-resistant mutants also lie within regions
II and III (37, 38, 41). These are a tyrosine to histidine change
in a HSV type 2 mutant at position 696 that confers aphidi-
colin resistance and hypersensitivity to PAA (41), an alanine
to valine change at position 719 in two mutants that are PAA
and ACV resistant (37, 38), an asparagine to serine mutation
at position 815 in three ACV-resistant mutants that differ with
respect to sensitivities to other drugs, and a glycine to serine
change at position 841 in a fourth ACV-resistant mutant (37).
Thus, there is a cluster of four mutations in region II and a
cluster offive mutations in region III. Given this grouping and
the high degree of sequence similarity among these regions in
evolutionarily distant cellular and viral DNA polymerases,
we consider it likely that amino acids within these regions
directly interact with substrates and drugs.
The mutation in PAArC lies between sequences designated
as region III and region VI (Fig. 2C), at a position only 7
amino acids from each region. In HSV pol, these two regions
are separated by only 13 amino acids, leaving open the
possibility that these two regions define a single continuous
sequence. In other DNA polymerases, however, these re-
gions are separated by longer variable stretches of primary
structure, ranging up to >60 amino acids (8). This gives rise
to the suggestion that the mutation in PAAFC might confer
altered drug sensitivity by altering HSV pol tertiary structure
such that region III is shifted relative to other portions of the
polymerase structure. That this mutation changes a proline to
an amino acid less likely to bend the polypeptide chain lends
strength to this suggestion.
Region V. Thus far, only one altered drug sensitivity
mutation, that of AraAr9, lies within the region of sequence
similarity designated region V. This result indicates a func-
tional role for region V. However, because any single
mutation could exert its effects on substrate and drug
recognition indirectly, we cannot yet say that it is likely that
region V interacts directly with substrates or drugs.
Roles of Other Regions of Sequence Similarity. No muta-
tions altering drug sensitivity have been found in regions I,
IV, and VI. It is especially interesting that this is true for the
region of greatest sequence similarity, region I. Since there
are a number of amino acids in these regions that are highly
variable among the viral and cellular polymerases, it seems
possible that these amino acids could be changed without
lethal effects. The construction of site-directed mutations in
these regions may be required to elucidate their roles.
Region A: A Region Involved in Drug Recognition That Is
Specific to Viruses That Are Sensitive to Certain Antiviral
Drugs. Two altered drug sensitivity mutations, tsD9 and
PFAr2, identify region A, a region of the HSV pol that is
involved in recognition of antiviral drugs but is not found in
human pol a. A third mutation, which has been reported to
confer resistance to PAA and ACV and hypersensitivity to
aphidicolin (43), also lies within this region, substituting
aspartic acid for glutamic acid at position 597 (37), the same
position that is altered in tsD9. Sequences highly similar to
this region are found in other herpesvirus DNA polymerases,
which generally are more sensitive to the inhibitors PAA,
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phosphonoformic acid, and the triphosphate derivatives of
ACV, ganciclovir, vidarabine, and BVdU than is human pol
a (44-47). A somewhat similar sequence can also be found in
vaccinia virus DNA polymerase, which appears to be rela-
tively sensitive to PAA, phosphonoformic acid, and ACV
triphosphate (48-50); however, adenovirus DNA polymerase
does not appear to contain such a sequence and adenovirus
DNA replication seems to be relatively resistant to PAA (49).
Thus, this region appears to be specific to viruses that are
sensitive to certain antiviral drugs. We suggest that this
region interacts either with drugs and substrates or with other
regions of the polymerase in a way that allows viral DNA
polymerases to be more sensitive to various antiviral drugs
than human pol a. Further understanding ofsuch interactions
could lead to design of more targeted antiviral drugs.
Individual Regions vs. Interacting Regions in Forming
Binding Sites. When these studies began, we thought that it
might be possible to identify stretches of amino acids in-
volved solely in dNTP binding, because certain mutants (30,
31, 42) exhibit altered sensitivity to nucleoside analogs, but
little or none to PP1 analogs. Indeed, Larder et al. (37) have
hypothesized that region III sequences have a direct role in
nucleotide binding rather than in pyrophosphate exchange
based on a mutation in that region found in three mutants that
are highly resistant to ACV and 2- to 5-fold more sensitive to
PAA than their wild-type parent. However, mutants in region
III, including mutant AraArl3 in the core of the sequence
similarity, can be as resistant to PAA as mutants in region II,
which Larder et al. (37) hypothesized tentatively to be the PP,
binding site.
In the three regions we have identified that contain more
than one mutation, given mutations can confer altered sen-
sitivity to PP1 analogs, nucleoside analogs, and/or aphidico-
lin. We cannot therefore identify any region as the sole
binding site for any of the drugs or substrates. Instead, we
favor a model in which interactions among the various
regions help form the binding sites for PP1 and dNTPs. Such
a model predicts that one should be able to isolate mutations
in one region that can suppress temperature-sensitive or
altered drug sensitivity mutations in another region. We have
isolated partial revertants of certain of the mutants studied
here, and their analysis, as well as physical studies, should be
useful in determining specific amino acid residues that
interact at the substrate binding sites in the protein.
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